CAR T therapy achieves high remission rate in acute lymphoblastic leukaemia trial
Trial data shows 71 percent of adult B cell acute…
Trial data shows 71 percent of adult B cell acute lymphoblastic leukaemia patients receiving Tecartus® autologous anti-CD19-transduced CD3+ cell infusion achieved complete remission.